Focal Segmental Glomerulosclerosis clinical trials

Apr 20, 2026

For decades, patients with focal segmental glomerulosclerosis had no approved treatment. Then Travere Therapeutics did the unthinkable: it turned a Phase 3 setback into a historic approval. Imagine being diagnosed with a progressive kidney disease, one that scars your kidneys from the inside, strips proteins fro...

May 20, 2025

Incyte’s ZYNYZ Approved by FDA as First-Line Treatment for Advanced Anal Cancer The FDA approved ZYNYZ (retifanlimab-dlwr), a PD-1 inhibitor developed by Incyte, for the treatment of adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC). The approval incl...

Sep 16, 2022

Currently, there are no FDA-approved therapies for FSGS. However, the therapeutic focal segmental glomerulosclerosis market in the seven major geographies mainly comprises off-label focal segmental glomerulosclerosis treatment options. The off-label therapies majorly include nonimmune therapies in conjunction wi...